Duality Biotherapeutics Says Phase 3 Breast Cancer Trial Met Primary Endpoint
Duality Biotherapeutics said its global DYNASTY-BREAST02 Phase 3 clinical trial met its primary endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.